Indianapolis-based Eli Lilly announced the closing of the company’s Surrey, U.K.-based Erl Wood neuroscience research center by the end of 2020, affecting 270 staffers.
Pfizer Inc. is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in the company’s efforts to become a major player in gene therapy.
Adaptive Biotechnologies announced plans to lease a new corporate headquarters, tripling the company’s footprint in Seattle.
Akorn Inc. received a warning letter from the U.S. Food and Drug Administration regarding a manufacturing facility in New Jersey, the latest in a string of setbacks for the generic drugmaker, sending the company’s shares down nearly 13 percent.
Contract research organization Catalent plans to buy Bristol-Myers Squibb’s manufacturing and packaging factory in Anagni, Italy, used to manufacture oral solid, biologics and sterile products.
With the acquisition of Shire, Takeda Pharmaceutical is building up the company’s research and development presence in the United States. Additionally, Insulet Corporation is celebrating the grand opening of the company’s new global headquarters and U.S. manufacturing facility in Acton, Mass.
Merck & Co. filed with the U.S. Securities and Exchange Commission that the company plans an extensive restructuring of its manufacturing and supply network.
Lilly inked a deal with Eddingpharm for the rights to two legacy antibiotic medicines and a manufacturing facility in Suzhou, China.
U.S. drugmaker Pfizer Inc. said the company was shutting down two manufacturing plants in India that make generic injectables such as penicillin in response to falling demand.